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 In eukaryotes, DNA methylation is an epi-
genetic mechanism that facilitates the 
transfer of methyl (-CH3) groups onto 
cytosine, aff ecting the expression of CpG-
rich genes. During times of metabolic 
stress and infl ammation, a coordinated 
transcriptome remodeling process occurs 
in order to maintain cellular homeostasis. 
Emerging evidence indicates that several 
transcriptional regulators, such as hypoxia-
inducible factor, nuclear factor-  B, activat-
ing protein-1, stimulatory protein-1, 
p53, Mys, and interleukin-6, are essential 
mediators of cellular stress and cellular 
homeostasis. 1 
 Although epigenetic mechanisms play 
important roles in the pathogenesis of 
various human diseases, their role in 
chronic kidney disease (CKD) is unclear; 
however, the plethora of metabolic altera-
tions and coexisting infl ammation that 
occur in CKD could potentially involve 
and induce diverse epigenetic changes. 
During progression of CKD, kidneys lose 
their ability to eff ectively remove toxic 
compounds from the body. Th e accumu-
lation of these uremic toxins is associated 
with the progression of glomerular and 
interstitial fi brosis at the transcriptional 
level. Th e increased levels of uremic toxins 
can stimulate the production of reactive 
oxygen species, deteriorate renal function, 
and promote progression of CKD. Most 
studies have focused on how these uremic 
toxins have aff ected the phenotype, but 
few have focused on the underlying 
molecular mechanism. 
 Several factors, such as infl ammation, 
oxidative stress, and uremic toxins, are 
characteristic of CKD 2 and progressive 
 kidney function deterioration, all of which 
could contribute to epigenetic alternation. 
Stenvinkel  et al. 3 demonstrated the corre-
lation between DNA methylation and 
infl ammation among CKD patients. DNA 
hypermethylation with lower ratios of HpaII 
to MspI is associated with cardio vascular 
disease. Th e same phenomenon has also 
been observed in end-stage renal disease 
patients. Th e connection between infl am-
matory factors and hypermethylation could 
be due to interleukin-6-mediated upregula-
tion of DNA methyltran sferase (DNMT) 
proteins and therefore has an impact on the 
cellular epigenome in a kidney undergoing 
an infl ammatory response. 4,5 
 Recently, the importance of the phos-
phaturic hormone fibroblast growth 
factor-23 and its necessary cofactor 
KLOTHO in the process of CKD was 
reported. 6 KLOTHO is a transmembrane 
protein, but because of alternative splic-
ing, two non-membrane-bound circulat-
ing protein subtypes also exist. The 
predominant distribution of KLOTHO is 
in the kidneys and in the parathyroid. 
Although the biological functions of 
KLOTHO are not entirely understood, 
KLOTHO has been identifi ed as having 
important roles in anti-aging, mineral 
metabolism, and vitamin D metabolism. 
Several  in vivo experiments using animal 
models that correspond with human 
kidney diseases have indicated that 
KLOTHO mRNA and protein levels are 
reduced during acute or chronic kidney 
diseases in response to reactive oxygen 
species. 7 Conversely, the overexpression 
of  Klotho in a transgenic mouse model, 
compared with the wild-type mice, exhib-
ited better renal function, less calcifi ca-
tion, and increased suppression of the 
insulin-like growth factor-1 (IGF-1) signal-
ing pathway. Th e IGF-1 signaling pathway 
is one of the most important pathways for 
compensatory renal hypertrophy after 
uninephrectomy. 8 Taken together, these 
published data indicate that KLOTHO is 
a potential key factor in response to 
renal dysfunction. 
 Sun  et al. 9 (this issue) used  in vitro 
cell models and  in vivo animal models of 
uremia-related CKD under oxidative 
stress conditions in an attempt to examine 
DNMT protein expression patterns and 
their role in DNA hypermethylation of 
important CpG islands. Th is information 
is important because of its novelty in the 
CKD fi eld as well as illustrating important 
physiological functions of KLOTHO 
in cancer. 
 Indoxyl sulfate and  p -cresyl sulfate are 
two protein-bound molecules that are 
carried into the renal tubular lumen by 
multiple organic anion  transporters. 10 
In an experimental CKD mouse model, 
indoxyl sulfate and  p -cresyl sulfate were 
used as a source of uremic toxins. Despite 
the continuous infusion of these uremic 
toxins, renal function indicators including 
blood, urine, nitrogen, and creatinine were 
not signifi cantly diff erent. Th e remnant 
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kidney exhibited a severe degree of fi brosis 
and high serum levels of uremic toxins. 
Taken together, these results parallel the 
progression symptoms of CKD. Th e mod-
ifi ed model also mimicked the progressive 
nephron loss and maintained the high 
level of uremic toxins caused by a per-
petual infl ammatory state, which oft en 
occurs in human CKD. 9 On the basis of 
the analysis of DNMT expression and the 
methylated status of the  Klotho gene by 
methylation-specific PCR, the authors 
hypothesized that the uremic toxin-
induced oxidative stress could potentially 
stimulate DNMT upregulation and even-
tually result in the alternative splicing 
of the  Klotho gene. It will be interesting 
to use the  in vivo experimental model 
to investigate uremic toxin-induced injury 
in the remnant kidney during CKD and to 
determine whether  Klotho is an eff ective 
biomarker for CKD. 
 In support of this hypothesis, the combi-
nation of uremia-related cell and animal 
model manipulations with decitabine 
(5-aza-2  -deoxycytidine), an inhibitor of 
DNMT activity, which is also used clinically 
in patients with myelodysplastic syn-
drome, 11 resulted in a reduction of the 
methylated status of the  Klotho gene and 
improved the expression of the KLOTHO 
protein signifi cantly ( Figure 1 ). Mechanism-
based studies suggest that decitabine is a 
cytidine analog that forms irreversible cova-
lent bonds with DNMT at cytosine sites 
targeted for methylation, and could modu-
late the uremic toxin-induced DNMTs. 
 In conclusion, the work by Sun  et al. 9 
provides a new window in research on 
uremia-related CKD and the epi genetic 
effect of uremic toxins such as indoxyl 
sulfate and  p -cresyl sulfate on the  Klotho 
gene. Uremic toxin-induced DNMT expres-
sion was involved in the silencing of the 
 Klotho gene through hypermethylation. 
Treatment with DNMT inhibitors may alter 
the hypermethylated status of the  Klotho 
gene and thus reverse the expression level. 
Although recent studies have indicated that 
the KLOTHO protein acts as a key modula-
tor in the homeostasis of renal function, 
including mineral and vitamin D metabo-
lism, this study provides us with new insight 
into the regulation of KLOTHO in the pro-
gressive decline of CKD via epigenetic 
modifi cation. With increasing advances in 
our understanding of epigenetic mechan-
isms involved in CKD, more opportunities 
for preventive and therapeutic intervention 
will arise. Epigenetic targeting of specifi c 
genes may become an important thera-
peutic strategy to prevent the progression 
of uremia-related CKD. 
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 Figure 1  |  Potential mechanisms of uremic toxin-induced silencing of the  Klotho gene in 
chronic kidney disease involve DNA methyltransferase-mediated regulation. 5-Aza-2dC, 
5-aza-2  -deoxycytidine; DNMT, DNA methyltransferase; FGF23, fibroblast growth factor-23; 
IGF-1, insulin-like growth factor-1; TF, transcription factor; TGF-  , transforming growth factor-  . 
